文献速递妇科

AdvanTIG-202:ociperlimab联合替雷利珠单抗与替雷利珠单抗单药治疗既往经治复发或转移性宫颈癌的2期开放标签、两队列多中心研究

AdvanTIG-202: Phase 2 open-label, two-cohort multicenter study of ociperlimab plus tislelizumab and tislelizumab alone in patients with previously treated recurrent or metastatic cervical cancer.
PubMed 文献 · Gynecol Oncol · 2025-05-23

本研究为2期开放标签两队列多中心研究,纳入既往接受过至少一线化疗且不适合根治性治疗的复发或转移性宫颈癌患者。第1阶段80例按1:1随机接受ociperlimab 900 mg联合替雷利珠单抗200 mg每3周方案(队列1)或替雷利珠单抗单药(队列2);第2阶段队列1额外入组98例。主要终点为盲态独立审查委员会依据RECIST v1.1评估的队列1中PD-L1+亚组和全人群的客观缓解率。

要点

  • 队列1 PD-L1+亚组客观缓解率为27.4%(95% CI 18.2%-38.2%),全人群为23.2%(95% CI 16.4%-31.1%)。
  • 队列1全人群中位无进展生存期为3.0个月(95% CI 2.6-4.9),PD-L1+亚组为4.1个月(95% CI 2.7-6.9)。
  • 队列1中70.3%发生至少1例治疗相关不良事件,18.1%发生至少1例≥3级治疗相关不良事件。

核心结论

  • 在既往接受过化疗的复发或转移性宫颈癌患者中,ociperlimab联合替雷利珠单抗在全人群和PD-L1+亚组均显示出有前景的抗肿瘤活性,支持进一步研究免疫调节剂联合方案用于复发或转移性宫颈癌。

研究设计与样本

  • 2期开放标签、两队列多中心研究。
  • 患者为复发或转移性宫颈癌,既往接受过至少1线化疗,且不适合根治性治疗。
  • 第1阶段80例患者按1:1随机分配至ociperlimab 900 mg联合替雷利珠单抗200 mg每3周方案(队列1)或替雷利珠单抗单药(队列2)。
  • 第2阶段队列1额外入组98例患者。
  • 2021年3月2日至2021年12月15日期间共入组178例患者,均接受治疗(队列1:138例;队列2:40例)。

主要发现

  • 队列1 PD-L1+亚组客观缓解率为27.4%(95% CI 18.2%-38.2%),全人群为23.2%(95% CI 16.4%-31.1%)。
  • 队列1全人群中位无进展生存期为3.0个月(95% CI 2.6-4.9),PD-L1+亚组为4.1个月(95% CI 2.7-6.9)。
  • 队列1全人群中位总生存期为12.2个月(95% CI 9.9-16.6),PD-L1+亚组为16.4个月(95% CI 10.4个月-不可估计)。
  • 队列1中70.3%发生至少1例治疗相关不良事件,18.1%发生至少1例≥3级治疗相关不良事件。
  • 队列1中35.5%发生免疫介导的不良事件。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Investigate the efficacy/safety of ociperlimab (anti-TIGIT monoclonal antibody [mAb]) + tislelizumab (anti-PD-1 mAb) in recurrent/metastatic (R/M) cervical cancer (CC). METHODS: Patients had R/M CC, received ≥1 prior chemotherapy, and were not amenable to curative treatment. In stage 1, 80 patients were randomized 1:1 to ociperlimab 900 mg + tislelizumab 200 mg every 3 weeks (cohort 1) or tislelizumab monotherapy (cohort 2). In stage 2, 98 additional patients were enrolled in cohort 1. Primary endpoint was blinded independent review committee-assessed objective response rate (ORR) by RECIST v1.1 for PD-L1+ subgroup and all-comers in cohort 1. RESULTS: Between March 2 and December 15, 2021, 178 patients were enrolled, and all were treated (cohort 1: 138; cohort 2: 40). ORR of cohort 1 PD-L1+ subgroup and all-comers were 27.4% (95% CI 18.2%-38.2%) and 23.2% (16.4%-31.1%), respectively. In cohort 1, median progression-free survival (PFS) was 3.0 months (95% CI 2.6-4.9) (all-comers) and 4.1 months (95% CI 2.7-6.9) (PD-L1+); median overall survival was 12.2 months (95% CI 9.9-16.6) (all-comers) and 16.4 months (95% CI, 10.4 months-not estimable) (PD-L1+). 70.3% of cohort 1 had ≥1 treatment-related adverse event (TRAE); 18.1% experienced ≥1 grade ≥3 TRAE. Immune-mediated AEs occurred in 35.5% of cohort 1. CONCLUSIONS: In patients with R/M CC who had received prior chemotherapy, ociperlimab + tislelizumab has promising antitumor activity in both all-comers and PD-L1+ subgroup, supporting further investigation of immune-modulating agent combinations for R/M CC. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04693234; https://clinicaltrials.gov/study/NCT04693234?term=NCT04693234&rank=1; EudraCT: https://eudract.ema.europa.eu/2020-004657-77.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Lee JY, Boonyapipat S, Yuan G, et al. AdvanTIG-202: Phase 2 open-label, two-cohort multicenter study of ociperlimab plus tislelizumab and tislelizumab alone in patients with previously treated recurrent or metastatic cervical cancer. Gynecol Oncol. 2025. PMID: 40411966. doi:10.1016/j.ygyno.2025.04.579

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。